Elicio Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
ELTX$1.65+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $17,618 | $12,894 |
| Restricted cash, current | 1,178 | 722 |
| Prepaid expenses and other current assets | 1,897 | 2,732 |
| Total current assets | 20,693 | 16,348 |
| Property and equipment, net | 483 | 717 |
| Operating lease, right-of-use assets | 5,706 | 6,563 |
| Restricted cash, noncurrent | 696 | 685 |
| Other long-term prepaid assets | 600 | 2,833 |
| Total assets | $28,178 | $27,146 |
| Liabilities, convertible preferred stock, and stockholders’ (deficit) equity | ||
| Current liabilities | ||
| Accounts payable | $1,038 | $4,369 |
| Accrued expenses | 8,415 | 3,757 |
| Deferred research obligation | 1,169 | 694 |
| Operating lease liability, current | 901 | 910 |
| Unvested option exercise liability, current | — | 25 |
| Total current liabilities | 11,523 | 9,755 |
| Warrant liabilities | 2,828 | 11 |
| Operating lease liability, noncurrent | 5,105 | 6,007 |
| Convertible note - related party | 20,034 | — |
| Total liabilities | 39,490 | 15,773 |
| Stockholders' (deficit) equity: | ||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.01 par value; 300,000,000 shares authorized; 11,043,837 and 9,618,178 shares issued at December 31, 2024 and 2023, respectively; 11,029,382 and 9,603,723 shares outstanding as of December 31, 2024 and 2023, respectively | 110 | 96 |
| Treasury stock, at cost, 14,455 shares outstanding | (150) | (150) |
| Additional paid-in capital | 183,004 | 153,827 |
| Accumulated other comprehensive loss | (175) | (197) |
| Accumulated deficit | (194,101) | (142,203) |
| Total stockholders' (deficit) equity | (11,312) | 11,373 |
| Total liabilities, convertible preferred stock, and stockholders’ (deficit) equity | $28,178 | $27,146 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.